Skip to content

State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder

Leslie A. Morland, Barbara O Rothbaum, Lauren M. Sippel, Jessica L Maples-Keller, Paula P. Schnurr

Journal of Traumatic Stress March 12, 2026 DOI: 10.1002/jts.70060 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Randomized Peer reviewed
Population Adults with PTSD
Topics MDMA Psychedelic-assisted therapy PTSD
Keywords Posttraumatic stress Cognition Cognitive behavioral therapy Leverage statistics Cognitive therapy Action physics Intervention counseling Randomized controlled trial Psychotherapist Clinical psychology Scientific literature Medline Clinical trial
Citations 2
Key findings MDMA-assisted psychotherapy for PTSD has shown promising outcomes in randomized controlled trials but faces significant methodological limitations and has not received FDA approval due to insufficient evidence.

Abstract

There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promising outcomes in recent randomized controlled trials, with high response and remission rates. However, the U.S. Food and Drug Administration declined to approve MDMA-AT for marketable use in August 2024 due to concerns about insufficient evidence. This paper reviews the current state of the scientific literature on MDMA-AT for PTSD, including putative mechanisms of action; key strengths and limitations of methodologies used to date; gaps in the evidence; and clinical, ethical, and regulatory considerations. Key limitations to be addressed in future studies include challenges with blinding, a lack of active comparator conditions, a lack of head-to-head comparisons of different models, inadequate safety monitoring, and limited sample generalizability. We describe emerging research that integrates MDMA with established trauma-focused therapies, such as prolonged exposure therapy and cognitive processing therapy, to leverage MDMA's effects on known cognitive behavioral mechanisms of action and support future implementation. Future research directions for advancing knowledge and consideration for the dissemination of MDMA-AT are discussed.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • State of the evidence: MDMA and psychedelic-assisted therapy Mixed

    Reports promising response and remission rates in randomized trials but notes the FDA declined approval in August 2024 due to insufficient evidence, citing blinding, comparator, safety-monitoring, and generalizability limitations.

    Synthesized

Comparable studies

Other narrative reviews on MDMA and psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. 2016 Review
MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? 2018 Review
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline 2019 Review
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy 2019 Review
MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis 2021 Review

Citations in the library

Cited by 1

Cites 30

and 25 more in the library

Related reading

Explore topics

MDMA Psychedelic-assisted therapy PTSD Addiction

By condition and practice

MDMA and psychedelic-assisted therapy MDMA for PTSD